BluLine PhotoTherapy, is a validated LED-based device to treat Neonatal Jaundice. Phototherapy has been the proven gold standard for the treatment of neonatal jaundice in both the developing and the developed worlds. BluLine Phototherapy is offered at a significantly lower price to developing countries. Beyond price, BluLine PhotoTherapy provides a complete phototherapy solution to health centers in developing countries.
Safety: LED’s do not emit harmful UV rays like other available phototherapy light sources. The device is currently being field tested in Honduras, Tanzania, and Nicaragua. .
Clinical Advantage: LED phototherapy treatment is proven to be more effective in decreasing bilirubin levels in the blood than fluorescent tubes and incandescent bulbs, while delivering more consistent treatment dose over time.
Size: Approximately the size of a boomerang, BluLine PhotoTherapy is very convenient for shipping purposes and transportation within the facility.
Portability: BluLine PhotoTherapy can be relocated from crib to crib versus a dedicated, stand-alone unit.
Longer Life Span: LED technology typically last twenty times longer than fluorescent tubes and incandescent bulbs and does not require periodic maintenance or replacement of LEDs.
Efficient: LED technology consumes significantly less power than fluorescent tubes
Reliability: A rechargeable battery offers 24 hours
of uninterrupted power supply.
With over two million cases last year, neonatal jaundice, also known as hyperbilirubinemia, is one of the most common conditions requiring medical attention in newborns. Shockingly, it affects 80% of premature and 50% of full-term babies. Infants are prone to jaundice because their livers are not yet fully developed. This results in an accumulation of serum bilirubin in their bloodstream.
This accumulation of this neurotoxin, without medical treatment, can cause death. Alternatively, it may cause a lifelong neurological condition called kernicterus in infants who survive. Kernicterus damages the newborn's brain. It may lead to deafness, severe developmental disabilities and athetoid cerebral palsy. With medical intervention, the rise in bilirubin levels can be curtailed and toxic accumulation can be avoided.
Tragically, although this is the most easily preventable of all brain damage causes through an inexpensive, simple treatment called phototherapy, this disease remains untreated in developing nations. The needs of the developing world have not been addressed for this disease state. This results in millions of unnecessary deaths and impairments each year.
Phototherapy has been the proven gold standard for the treatment of neonatal jaundice in both the developing and the developed worlds. Phototherapy is an uncomplicated and safe method of treatment. The affected infant is simply placed under blue light (~ 460 nm wavelength) for specified time periods. The light converts the bilirubin into a form that can be eliminated from the body. Repeated exposures over the course of a few days are typically sufficient to return the infant to normal good health.
Over 50 published, controlled trials confirm the clinical use of phototherapy to effectively prevent and treat hyperbilirubinemia. Additionally, phototherapy dramatically reduces the need for a blood transfusion.
Historically, phototherapy devices used fluorescent tubes for treatment. A new method to deliver high-intensity, narrow-band light has been developed using gallium nitride light emitting diodes (LEDs). LEDs permit high irradiance in the spectrum of choice with minimal heat generation. LED phototherapy units are FDA approved and are commercially available in the US and Europe. Our solution utilizes this newer approach, while integrating the concerns of the developing world.